Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. Lau SCM, Fares AF, Le LW, Mackay KM, et al. Clin Lung Cancer 2021;22:253-259.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lau SCM, Fares AF, Le LW, Mackay KM, et al. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. Clin Lung Cancer 2021;22:253-259.
PMID: 33582070